April 2, 2026
Pharma news March 17-30: Big M&A by Novartis & Merck, strong VC funding, positive Phase 2/3 data in obesity & CNS, plus 6 FDA approvals.
March 19, 2026
Pharma & biotech sees major deals in autoimmune & oncology, promising late-stage data in obesity & MS, and key FDA label expansions.
March 5, 2026
Biopharma heats up with Gilead's $7.8B Arcellx acquisition, major VC funding in CNS, pivotal obesity data, and a wave of FDA approvals.
February 18, 2026
Pharma deals surge with Lilly, Takeda, & Genentech. VC funding flows to oncology & immunology. Key Phase 3 data & FDA CRLs shape pipelines.
February 5, 2026
Biopharma dealmaking surges in oncology and obesity, VC funding favors novel platforms, while major late-stage clinical wins contrast with a key FDA rejection.
January 21, 2026
JPM 2026 sparks a deal-making frenzy! This report covers major bio-partnerships, massive VC rounds, key Phase 3 readouts, and FDA decisions.
January 6, 2026
Pharma deals surged with Sanofi's $2.2B Dynavax buy & AZ's $1.9B+ oncology pact. FDA approved 4 new drugs despite 2 major trial failures.
December 24, 2025
Pharma & Biotech Update: Major partnerships (Pfizer, Sanofi), huge VC rounds for AI & neuropsychiatry, positive Phase 3 data, & new FDA approvals.
